The Anniversary of the Co-E-Plate . . . Pharmaceutical stock market value TOP10 announced waiting for listed companies to source concentration

On June 13, 2019, the board officially opened, and it has been the first anniversaryDuring the year, 67 biopharmaceutical companies have filed for listing, 26 have successfully launched their ipos, and 41 have now filed pending approvalaverage in less than 3 days, one company goes public, every 12.5 days a biopharmaceutical stock landingthis is the speed at which the board has been implemented since it opened on June 13, 2019As of June 12, 110 companies were listed, with a total market capitalization of 1.72 trillion yuan, of which 26 were biopharmaceutical companies, accounting for 22.6%In addition, as of June 7, a total of 296 companies have been declared, including 67 biopharmaceutical companiesin terms of market value, co-production board produced a total of two hundred billion market value enterprises - Jinshan Office and Micro, the total market value of 119.247 billion yuan and 110.08 0 billion yuanIn addition, there are 47 companies with a market capitalization of more than 10 billionThe highest market value of biopharmaceutical companies was Huaxi Bio, at $61.1 billion, far more than any other similar companyAt present, a total of 26 biopharmaceutical companies listed, with a total market value of 387.5 billion yuan, with its number accounting very close, market value is also about 22.5%even in the entire A-share market, Huaxi Bio's market capitalisation is in the top 20Founded in 2000, Huaxi Bio is the world leader in hyaluronic acidIn the past two years, its growth rate has entered a fast track: total operating income of RMB1,263 million and RMB1,886 million were realized in 2018 and RMB1,886 million, respectively, up 54.41 percent and 49.28 percent year-on-year, respectively, and net profit attributable to shareholders of the parent company was RMB424 million and RMB586 million, up 38.16 percent yoY in 2019as a segment of the leading enterprises, most will embark on an industrial chain extension roadIn 2012, Huaxi Bio began to expand downstream end products, the implementation of the whole industrial chain layoutTo date, Huaxi Bio has formed three business segments covering upstream hyaluronic acid raw materials as well as downstream medical end products and functional skin care productsin addition, due to the impact of the outbreak at the beginning of the year, many pharmaceutical stocks share prices rose, and even many enterprises through the outbreak of market value doubled, therefore, in the pharmaceutical stocks market value of more than 10 billion enterprises, a higher proportion of 55.6%, and the overall board in 42.7% as of the close of trading on June 12, 15 of the biopharmaceutical companies have a market value of more than 10 billion, in addition to Huaxi Bio, Nanmicro Medicine, BaiOtai, Microcore Bio, Borui Pharmaceuticals followed closely behind, with a market value of 20-30 billion, Tebao Bio, Chengdu Pilot, Zeyi Pharmaceuticals, Cardiology Medical and Oriental Bio ranked 6-10, with a market value range of 160-20 billion It can be seen that the market value threshold of top10 of pharmaceutical stocks is 16 billion yuan the first year since the opening of the board, in the field of biomedicine medical equipment is greater than the situation of medicine has not changed, medical equipment, equipment and supplies enterprises more than half However, in the market value of TOP10 enterprises, pharmaceutical companies reached six, respectively, micro-core, Baxter, Tebao, Zeru, pilot and Berry of the 26 biopharmaceutical companies currently with a market capitalisation of less than $5 billion, only Heatview Bio and MedI as of June 10, a total of 41 biopharmaceutical enterprises lined up to declare the board, waiting for the listing, of which the faster progress of Yuandong Biology, Key Kai Technology and so on have passed 25 of the 41 enterprises are pharmaceutical manufacturing enterprises, the rest are medical equipment manufacturing enterprises, research and test development enterprises, chemical raw materials and chemical selling enterprises Pharmaceutical companies are already catching up with medical companies by E drug managers statistics, these 41 enterprises mainly from Jiangsu, Shanghai and Beijing, the number of declared enterprises in these three places are 9, 8, 8, the total proportion of more than 60%, followed by Zhejiang, Guangdong and Hunan, the rest of the provinces and autonomous regions either no pharmaceutical enterprises to declare, or only one And has been successfully listed enterprises, registered in Jiangsu, Shanghai, Beijing and a few other areas are also the most, it can be seen that the geographical concentration of listed enterprises will become more and more obvious in addition, the opening of the board, but also attracted a number of Hong Kong stock companies or listed companies to spin off the listing For example, the recent Weigao, Liaoning Chengda, Changchun High-tech and other announced the spin-off of the subsidiary landing board, following Junshi, Kangsino, stone medicine recently also announced the consideration of science board listing, TianshiLi biological is by the Hong Kong stock re-reporting board since the opening of the Hong Kong stock market to welcome biotech and last year's opening of the board, the two sectors have become both the flow of pharmaceutical companies in both directions The trend of pharmaceutical enterprises in pursuit of "A-H" stocks seems to have not stopped, a number of star stocks in the future or will be "Dengke", Hong Kong stocks have also become an important "source" of science and technology board enterprises after a year of trial and wait-and-see, pharmaceutical companies for the company's enthusiasm for the board does not seem to have declined, some enterprises are gradually dispelling concerns, more confidence in this new board considering the listing of the company, Ishiguro said it would continue to use financial leverage to further leverage innovative high-tech capital markets, adding that "the capital is for high-quality development" Junshi also expressed three reasons for its choice of science and technology board: first, the SSE market is more mature, and the broader range of investors, can improve the company's market recognition; notable, CICC predicted in a May 24 report that some red chips could return to A-shares, including Stone Pharmaceuticals, and companies such as China Biopharmaceuticals, Henson Pharmaceuticals, Cinda Bio, PharmaceuticalS.